It is well known that intracellular antioxidant glutathione (GSH) plays major roles in the maintenance of redox status and defense of oxidative stress. Ras, a small GTPbinding protein, may send growth-stimulating message to the nucleus through downstream Rac oncoprotein and superoxide (O 2 À ). These findings led us to investigate the effects of GSH and melatonin, a free-radical scavenger, on Ras-Rac-O 2 À -related growth signal transduction. Our results demonstrate that overexpression of the inducible Ha-ras oncogene by isopropyl-b-d-thiogalactoside (IPTG) increases the levels of reactive oxygen species (ROS, including O 2 À and hydrogen peroxide (H 2 O 2 )) and GSH in an Ha-ras-transformed NIH/3T3 fibroblast cell line. On the contrary, melatonin significantly suppresses ras-triggered cell growth by inhibiting the increase of ROS and GSH. Moreover, severe apoptosis of this transformed cell line occurred when the cell redox balance between ROS and GSH was dramatically changed in the presence of IPTG and l-buthionine-[S,R]-sulfoximine (BSO, a specific inhibitor of GSH synthetase). That BSO-induced cell apoptosis needs Ras to increase the ROS level was demonstrated by the free-radical scavenger melatonin. It effectively blocked cell apoptosis, but cell growth was also slowed without affecting Ras expression. Based on our studies, two approaches can be applied to treating ras-related cancers. One is utilizing melatonin to suppress cancer cell proliferation, and the other is utilizing BSO to induce cancer-cell apoptosis. Cotreatment of rasrelated cancer cells with melatonin and BSO stops cell growth as well as apoptosis. Whether these cancer cells will undergo further regression or become recurrent merits investigation.
Introduction
Reduction/oxidation (redox) reactions play a central role in the regulation of various cell functions. Recent evidence has demonstrated that a free radical of superoxide (O 2 À ) involved in the growth pathway of Ras-activated cells and in the treatment of cells with agents that abolish superoxide generation is able to inhibit the mitogenic effect of Ras (Irani et al., 1997; Joneson and Bar-Sagi, 1998) . On the contrary, overproduction of reactive oxygen species (ROS) has been implicated in the cause of cell death and neurodegenerative diseases, such as ischemic stroke, Parkinson's disease, and Alzheimer's disease (reviewed in Olanow, 1993; Beal, 1998) , and administration of antioxidants has neuroprotective action (Chen et al., 2002) . Thus, it has been proposed that superoxide and probably other oxidants serve as messengers for normal signal transduction at lower concentrations; at higher concentrations, however, they become toxic and can induce cell damage (Irani and Goldschmidt-Clermont, 1998) .
Cells contain endogenous antioxidant defense enzymes to scavenge ROS and maintain the redox balance. The glutathione (GSH, l-g-glutamyl-l-cysteinyl glycine) redox system is an important antioxidant defense system involved in the protection of cells against oxidative damage and in various detoxification mechanisms (Griffith, 1999) . GSH is also a substrate of glutathione peroxidase (GSH-Px) that metabolizes GSH to its oxidized form (GSSG). Simultaneously, H 2 O 2 is converted to H 2 O and the generation of OH is reduced by eliminating its precursor (Meister, 1994) . Evidently, GSH and GSH-Px are important antioxidants, and the GSSG/GSH ratio is regarded as a sensitive indicator of oxidant stress (Guo et al., 1992) . Depletion of GSH by using the GSH synthetase inhibitor l-buthionine-[S,R]-sulfoximine (BSO) disturbs the redox balance and enhances the vulnerability of cells to oxidative stress (Toffa et al., 1997; Seyfried et al., 1999) . However, it has not been demonstrated whether the GSH antioxidant defense system interferes with Ras-triggered signals.
Melatonin, known as an antioxidant secreted from the pineal gland, can inhibit cell proliferation in a number of cell culture systems (Blask et al., 1997; Mayo et al., 1998; Petranka et al., 1999) . At physiological concentration (1 nm), melatonin decreases cell poliferation by inducing cell cycle arrest through increasing expression of p21WAF1 protein, which is mediated by p53 (Roth et al., 1997; Mediavilla et al., 1999) . On the contrary, melatonin acts as an antioxidant to prevent cell death elicited by oxidative stress (Chen and Chuang, 1999; Reiter et al., 2000; Chen et al., 2002) , whereas pinealectomy, which reduces endogenous melatonin level, leads to aggravate oxidative insult in focal ischemia (Kilic et al., 1999) . Ras is an initiator of many cancers (Guha, 1998; Weijzen et al., 1999) and melatonin shows oncostatic action in various cancer cells (reviewed in Karbownik et al., 2001) . Whether melatonin can counteract the Ras-involved functions remains unknown and is worth exploring.
To clarify the role of redox balance in controlling cell fate, we manipulated the redox status by (1) downregulating the GSH antioxidant defense system or (2) using the free-radical scavenger melatonin in mouse NIH/3T3 fibroblast-derived 7-4 cells, which harbor an inducible Ha-ras oncogene (Liu et al., 1998) . In this study, we demonstrate that transient ras overexpression by IPTG induction significantly increased the levels of ROS and GSH, and that the cells grew normally. If the cellular redox balance between ROS and GSH was disturbed by BSO, more cells underwent apoptosis while Ras was overexpressed. Melatonin significantly suppressed the ras-triggered cell growth and rescued cell apoptosis induced by BSO. Melatonin's action is through eliminating ROS generated from ras overexpression with or without BSO administration.
Results
Induction of apoptosis of 7-4 cell overexpressing Ha-ras by BSO and prevention by melatonin treatment The effect of BSO (an inhibitor of GSH synthetase) and melatonin (a free-radical scavenger) on morphological changes, viability, and apoptosis of 7-4 cells were investigated. Our data show that in the presence of IPTG (5 mm), 7-4 cells treated with BSO (100 mm) became aggregated, contracted, and clumped together. Some of the cells started floating and died 48 h after BSO treatment (Figure 1a, 10IB) . The BSO-induced morphological changes in ras-overexpressed cells were not found when the cells were cotreated with melatonin ( Figure 1a, 10IBM) . Cell viability significantly decreased in Ha-ras-overexpressed 7-4 cells after BSO treatment was further confirmed by a trypan blue-exclusion assay (Figure 1b, 10IB) . Comparatively, the BSO treatment caused only a slight loss of 7-4 cell viability without IPTG induction (Figure 1b, 10B ). Moreover, cell viability decreased by BSO alone or BSO and IPTG treatment can be effectively prevented by coadministration with melatonin (Figure 1b, 10BM and 10IBM vs 10B and 10IB) .
To clarify whether 7-4 cells after IPTG and BSO treatment undergo apoptosis, cells maintained in 10% serum-containing medium with IPTG plus BSO for 48 h were analysed by DNA fragmentation assay and MC 540 staining. Intensive internucleosomal DNA fragmentation was detected only in 7-4 cells treated with IPTG and BSO (Figure 1c, 10IB) , which indicates that GSH depletion by BSO could trigger Ha-ras-overexpressed cells to undergo apoptosis. The percentage of apoptotic cells visualized by MC540 stain was quantified by flow cytometric analysis. Ha-ras-overexpressed cells together with GSH depletion showed a higher apoptotic population (85.1%; Figure 2 , 10IB) than cells cultured in 10% serum-containing medium (5%; Figure 2 , Con). Without GSH depletion, Ha-ras overexpression per se could not induce cell apoptosis (6.3%; Figure 2 , 10I). BSO treatment alone could induce a small apoptotic population (25.4%; Figure 2 , 10B). Furthermore, cotreatment with melatonin blocked BSO-induced DNA fragmentation and apoptosis of 7-4 cells whether or not ras was overexpressed (Figures 1c and 2 , 10IBM or 10BM). Our results suggest that the impairment of the GSH antioxidant defense system played an important role in controlling cell fate. Once the function of antioxidant was lost together with ROS production, the redox status markedly shifted to oxidative stress, which triggered cell apoptosis. In addition, melatonin, a free-radical scavenger, shown in the following experiments (Figures 3 and  4) , counterbalances the oxidative stress to block cell apoptosis induced by BSO treatment.
Melatonin attenuates the increase of reactive oxygen species occurred in Ha-ras-transformed cells or BSO-treated cells
To determine if ROS is involved in the ras signaling pathway and examine whether the GSH reduction affects the production of ROS, 7-4 cells were incubated with 2 0 ,7 0 -dichlorofluorescin (DCFH ) or dihydroethidium (DHE) for the detection of H 2 O 2 or O 2 À , respectively, at 48 h after various treatments (Figures 3 and 4). Significant increases in the intensity of DCF and ethidine fluorescence were detected in IPTG-treated (10I), BSO-treated (10B), and IPTG plus BSO cotreated cells (10IB). The ras overexpression alone or in combination with BSO increased ROS, which was blocked by melatonin ( Figures 3 and 4 , 10IM, 10BM, 10IBM), which indicated that melatonin is a potent freeradical scavenger. Our results suggest that ras overexpression and GSH depletion can induce the generation of H 2 O 2 and O 2 À in 7-4 cells. A synergistic effect of superoxide production was observed while ras overexpression and GSH depletion coexisted in the cells.
Melatonin suppresses Ha-ras-triggered growth rate
To further confirm that ras-transformed cell growth is related to ROS production, we determined that melatonin eliminated the change in the rate of cell proliferation when ras-triggered ROS. Figure 5 demonstrates that melatonin significantly suppressed the proliferation of ras-overexpressed cells (10IM vs 10I), but did not affect the growth rate of parental 7-4 cells (10M vs 10%) at all times observed. The antiproliferative effect of melatonin is coincident with its ability to eliminate H 2 O 2 and O 2 À induced by Ha-ras overexpression (Figures 3 and 4, 10IM vs 10I). We also found that the inhibition of cell growth by melatonin was not due to the suppression of ras expression (data not shown). Our results clearly demonstrate that melatonin is an antiproliferative agent that suppresses ROS production in the cells induced by overexpression of the ras oncogene. Here, ras overexpression only slightly increases the growth curve 
Ha-ras overexpression increases GSH concentration but cannot reverse the GSH suppression by BSO
To elucidate the role of the GSH antioxidant system in Ha-ras-overexpressing cells or melatonin cotreated cells, the intracellular level of GSH and the ratio of GSSG/ GSH (oxidized GSH/total GSH, a sensitive marker of oxidative stress) were measured 48 h after the ras overexpression of 7-4 cells treated with BSO alone or with melatonin. As shown in Figure 6 , a significant increase in the GSH concentration without change in the GSSG/GSH ratio was detected in ras-overexpressed 7-4 cells (10I). In contrast, BSO treatment significantly decreased the GSH level and dramatically increased the ratio of GSSG/GSH (Figure 6, 10B ). All together, Ha-ras overexpression could not reverse the loss of GSH and elevation of the GSSG/GSH ratio induced by BSO (Figure 6, 10IB) . On the other hand, melatonin treatment reversed the increase of GSH induced by ras overexpression (Figure 6, 10IM ), but could not affect the BSO-induced GSH impairment ( Figure 6 , 10BM and 10IBM).
Discussion
In this study, we demonstrate that the action of ROS on controlling cell growth and death is dependent on the antioxidant defense status of the cell. We found that cell proliferation in 7-4 cells with Ha-ras overexpression correlated with increasing levels of H 2 O 2 , O 2 À , and GSH. In this case, the antioxidant GSH defense ability represented by an increase of GSH level counterbalanced the elevation of pro-oxidant ROS and thus caused cells to grow normally. Once the balance between ROS and GSH was disturbed by the free-radical scavenger melatonin or the GSH synthesis inhibitor of BSO, ras-overexpressed cells began to grow slowly or died, respectively (Figure 7) . In contrast, the behavior of 7-4 cells without ras overexpression was slightly affected by BSO because there was no overproduction of ROS to deteriorate the redox status. Although BSO and melatonin showed dramatic effects on cell fate, ras expression was not changed by either one (data not shown). These results support our hypothesis that cell proliferation triggered by ras overexpression is required to increase the levels of ROS and GSH and reach a new balance. It is consistent with other reports that superoxide production or GSH elevation are involved in rasdependent cell growth (Kuo et al., 1996; Irani et al., 1997) . Similarly, some reports state that GSH levels in many cancer cells were significantly higher than in was assessed using the probe 2 0 , 7 0 -dichorofluorescein diacetate (DCFH-DA). Cells were treated the same as described in Figure 2 for 48 h and incubated with DCFH-DA for 20 min at 371C in the dark. The intensity of DCF fluorescence of 10 000 cells from different treatments was detected by flow cytometry and shown as GM value. The GM value showing in each panel from panels b to h represents the amount of H 2 O 2 production and summarized in panel a (n ¼ 3). Abbreviations are the same as described in Figure 2 . * represents a significant difference compared with 7-4 cells cultured in 10% FCS medium (Con), # represents a significant difference compared with each corresponding group without melatonin treatment (Po0.05, ANOVA followed by Newmann-Keuls multiple comparison test) normal tissues, whereas suppression of GSH was able to inhibit cell growth and enhance cell apoptosis (Thrall and Meadows, 1991; Kuo et al., 1996; Barranco et al., 2000; Schnelldorfer et al., 2000; Vahrmeijer et al., 2000) . This is the first study showing that suppression of the GSH level triggered apoptosis in the ras-overexpressed cell. This finding may be applied as a useful adjuvant therapy in Ha-ras-related cancers. Our results also suggest that GSH is a downstream factor of ras because while ras overexpression increased the GSH level, GSH depletion did not alter ras expression. This is consistent with a previous report (Walsh and Lawrence, 1995) that no change of ras mRNA expression was detected by reducing the GSH level, but discordant with another (Miller et al., 1993) that the decline of cellular GSH content caused downregulation of ras mRNA expression and ras-encoded p21 protein production in Ha-rastransformed NIH 3T3 cells. The discrepancy is probably because of different cell types.
Our results further demonstrated that by eliminating H 2 O 2 and O 2 À production without altering ras expression, melatonin significantly decreased the proliferative À production and summarized in panel a Figure 5 Melatonin suppresses the growth rate of 7-4 cells overexpressing the Ha-ras oncogene. The cell number was counted at a 24 h interval for 5 days by the microassay (Ito, 1984) . The relative cell number is calculated as: cell number divided by cell number in 10% FCS medium (con, n ¼ 3). *Po0.05 compared to Ha-ras-overexpressed cells by ANOVA and Newmann-Keuls multiple comparison test rate of 7-4 cells overexpressing ras. Although some (Irani et al., 1997; Joneson and Bar-Sagi, 1998) have claimed that other antioxidants, such as N-acetyl-lcysteine (NAC) and superoxide dismutase (SOD), can inhibit the mitogenic activity in ras-transformed cells, this is first report that melatonin can block ras-induced cell growth, which provides a new insight for its oncostatic ability. Accumulated reports (Panzer et al., 1998; Cos and Sanchez-Barcelo, 2000; Marelli et al., 2000) showing that melatonin exerts oncostatic action that make it a potential supplement in the treatment of various cancers in vitro, in vivo, and in clinical therapy further support our hypothesis. Melatonin inhibits MCF-7 human breast cancer cell proliferation by inducing a G0/G1 arrest, which is dependent on an increased expression of p21WAF1 protein (Mediavilla et al., 1999) . Moreover, cell growth inhibition of melatonin presenting in several breast cancer cells can be blocked by BSO and restored by exogenous addition of GSH, indicating that GSH is required for the oncostatic action (Blask et al., 1997) . In addition, because the process of carcinogenesis often involves oxidative stress, based on the evidence provided, we hypothesize that the anticarcinogenic action of melatonin is due in part to its antioxidative and free-radical scavenging activities (Karbownik et al., 2001 ). Therefore, the oncostatic mechanism of melatonin is quite different from the mechanisms of other chemotherapeutic drugs.
In accordance with the apoptosis induced by decreased GSH and increased ROS, which also causes an imbalance between ROS and GSH, melatonin effectively prevented BSO-induced cell apoptosis by decreasing ROS level. Other reports indicate that oxidative insults and GSH reduction in various neurodegenerative models can be effectively prevented by melatonin treatment (Chen and Chuang, 1999; Reiter et al., 2000; Chuang et al., 2001; Chen et al., 2002) . Melatonin inhibits BSO-induced cataract formation in the newborn rat by reducing lipid peroxidation and the high ratio of GSSG/GSH (Abe et al., 1994; Li et al., 1997) . Moreover, we also found that melatonin abolished the upregulation of GSH and ROS induced by ras and subsequently retarded cell growth. Since ROS can act in either a proliferative or a destructive role by altering the intracellular redox milieu, we believe that melatonin has dual functions: suppressing cell growth and preventing cell apoptosis. It has also been Figure 6 Ha-ras overexpression increases GSH concentration but cannot reverse the GSH level suppressed by BSO. GSH level and GSSG/GSH ratio were detected in cells with the same treatments as described in Figure 2 . *Po0.05 and **Po0.01 compared to the cells cultured in 10% FCS medium (Con) Figure 7 A model for the balance between ROS and GSH in controlling cell fate. Ha-ras overexpression induces the increase of ROS and GSH level but does not affect the balance status. The cells grow normally. The antiproliferative effect of melatonin is attributable to the suppression of ROS and GSH, which were increased by ras overexpression. BSO depresses GSH antioxidant defense and consequently induces ROS production, which causes apoptosis of ras-overexpressed cells. Melatonin scavenges ROS to rescue rasoverexpressed cells from BSO-induced cell apoptosis reported (Roth et al., 1997; Mayo et al., 1998 ) that melatonin significantly attenuates apoptotic cell death induced by 6-hydroxydopamine (6-OHDA) at the same time as it inhibits undifferentiated rat pheochromocytoma (PC12) cell proliferation because of its antioxidant property.
Our results demonstrate two approaches to block the outgrowth of ras-related cancers: antiproliferative action by melatonin and inducing apoptosis by GSH depletion. Importantly, 7-4 cells overexpressing ras were more sensitive to these two effects than their parental NIH/3T3 cells. Although cell death induced by BSO (80%) is more significant than growth inhibition (20%) by melatonin, three additional advantages favor the use of melatonin in cancer therapy. First, its lipophilic property, not shared by BSO, allows melatonin to easily penetrate cell membranes and the blood-brain barrier (Griffith, 1999; Reiter et al., 2000) . Second, concomitant administration of melatonin with radiotherapy or chemotherapy is more effective than cancer therapy alone in enhancing survival time and tumor response rate (Lissoni et al., 1996 (Lissoni et al., , 1999 . Third, melatonin has been proven to counteract chemotherapy toxicity by acting as an antioxidant, such as neurotoxicity, cardiotoxicity, stomatitis, and asthenia (Lissoni et al., 1999; Agapito et al., 2001; Xu et al., 2001) . Melatonin also increases the efficacy of chemotherapeutic agents (Granzotto et al., 2001; Reiter et al., 2002) . Here, we demonstrate that melatonin markedly blocked apoptosis of cells manifesting ras-overexpression and GSH depletion, which suggests that it should be under consideration if coadministration of BSO and melatonin is used to treat ras-related cancer cells. Fourth, melatonin plays a critical role in the host defense system against the progression of neoplasia by activating the cytokine system, which exerts growth-inhibitory properties and/or by stimulating the cytotoxic activity of macrophages and monocytes (Neri et al., 1998) . Based on the multiple anticancer actions of melatonin, further investigation is required to confirm that clinical application of melatonin is beneficial for the treatment of ras-related cancer, especially because it is being used as a health food. In addition, the cellular redox status in the control of ras-related cancer growth should be seriously considered in the concomitant administration of antioxidants and chemotherapy, which induces oxidative stress.
Materials and methods

Cell culture and treatment
The 7-4 cells, which harbor an inducible Ha-ras oncogene (Liu et al., 1998) and contain the plasmids pSVlacOras and p3 0 SS, were maintained in minimal essential medium (a-MEM; Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum at 371C in a 5% CO 2 incubator. Isopropyl-b-d-thiogalactoside (IPTG; Gibco), a nonmetabolizable lactose analog, was added to induce expression of the Ha-ras transgene in the 7-4 cells.
Assessment of cell viability
Cell viability was assessed by trypan blue-exclusion assay or merocyanine 540 stain. At an appropriate time point after the exposure of various reagents, the cell pellets were collected and resuspended in HEPES-buffered saline and then stained with merocyanine 540 (MC 540; Sigma-Aldrich, St Louis, MO, USA) in the dark for 10 min (Chang et al., 1999) . MC 540, similar to Annexin V, can bind the phosphatidylserine (PS) of the extroverted inner membrane component during cell apoptosis and is used as an indicator of cell apoptosis. The 1 Â 10 4 cells were assayed by CellFIT software in a fluorescence-activated cell sorter (FACScan; Becton-Dickinson, Mississauga, Ontario, Canada). The cell growth curve was detected by a microassay as described previously (Ito, 1984) .
Determination of GSH, GSSG, and protein
To determine glutathione content, a monolayer of fibroblasts on 100-mm-diameter cell culture plates 48 h after treatment was washed twice with cold PBS. After removal of the residual liquid, 150 ml of 1% picric acid (Sigma) was added directly onto the cells. The precipitated protein and acid extract were transferred to an Eppendorf tube, briefly homogenized, and centrifuged at 14 000 g for 15 min. The acid-soluble fraction was used to measure GSH levels, and the protein pellet was used to determine protein concentration. Total GSH and oxidized glutathione (GSSG) were quantified as described previously (Chen and Chuang, 1999) . To determine the amount of GSSG, 2-vinylpyridine was used to destroy the reduced form of GSH, and then followed by the same GSH assay procedure. Protein concentration was determined with a Lowry assay. Bovine serum albumin was used as a protein standard.
Determination of intracellular ROS
Intracellular accumulation of H 2 O 2 and O 2 À were determined with DCFH (Sigma) and DHE (Sigma), respectively (Rothe and Valet, 1990) . The cells were harvested, 48 h after different treatments, and washed once with PBS. Cell pellets were resuspended and stained with 0.01 mm DCFH or DHE in 1 Â HBSS (Hank's balanced salt solution) for 15 min at 371C. These probes enter the cells and can be oxidized in the presence of ROS, generating the fluorescent compound DCF or ethidium. The intensity of fluorescence measured by flow cytometry is representative of the level of ROS production.
Western blot analysis
After incubation, the cell pellet was collected and homogenized in sodium dodecyl sulfate (SDS) sample buffer (125 mm Tris pH 6.8, 10 mm EDTA, 4% SDS, 15% sucrose, 100 mm DTT, 6 m urea). The cell debris were removed by centrifugation at 12 000 g for 20 min at 41C, and the protein concentration was determined with a Bio-Rad protein assay. An equal amount of protein from each sample was electrophoresed on 12% SDSpolyacrylamide gels and transferred to PVDF membranes (NEN) with a semidry blotting system. The membranes were washed and blocked with 5% nonfat dry milk in PBS containing 0.1% Tween 20. The membranes were then hybridized with monoclonal anti-Ras primary antibodies (Oncogene) at room temperature for 1 h. After being washed in PBST, membranes were incubated with biotine-conjugated sheep antimouse IgG antibody (1 : 1000) for 1 h. Immunoreactivity was detected by enhanced electrochemoluminescence autoradiography (ECL kit; Amersham Biosciences, Piscataway, NJ, USA).
DNA fragmentation
After the experiments, cell pellets were incubated with 100 ml extraction buffer (0.5% Triton X-100, 10 mm EDTA, and 10 mm Tris, pH 7.4). After centrifugation, the supernatants were incubated with 50 ml of RNase A (20 mg/ml) (AMRES-CO, Solon, OH, USA) and 20 ml of SDS (10%) at 561C for 2 h; 35 ml of proteinase K (20 mg/ml) was then added and the mixture was incubated at 371C overnight. DNA fragments were precipitated with 150 ml NH 4 OAc and 1.2 ml of 100% ethanol at À201C overnight. DNA pellets were recovered after centrifuging and drying. They were then resuspended in 20 ml Tris-EDTA buffer and electrophoresed on a 1% agarose gel in TBE buffer at 40 V for 8 h. Finally, the DNA ladder was visualized with ethidium-bromide staining under UV light.
